ÂÜÀòÂÒÂ×

Sissel Rodahl, has been appointed Senior Vice President of Commercial Operations since February 2022. Sissel joined GenSight after more than 25 years of professional experience in rare diseases and gene therapies where she held various commercial leadership roles of increasing responsibility, including at Serono, Merck KGaA, Shire, Raptor, Horizon and AveXis.

She was one of the first employees at AveXis for the EMEA region (Europe, Middle East and Africa) and played a key role in the development and execution of the go-to-market strategy for their first gene therapy. Following the acquisition of AveXis by Novartis, Sissel served as Vice President at Novartis Gene Therapies, where she successfully led the launch of their gene therapy in a group of 15 Western European countries.

Sissel Rodahl holds a Master's degree in Biochemistry from the University of Oslo, Norway, and a Bachelor's degree in Biotechnology from Oslo University College of Engineering.